Testing a new drug combo for inclusion body myositis
Part of Bones, joints & muscles, Brain & nervous system clinical trials.
This trial tests a combination of two investigational drugs (pozelimab and cemdisiran) to see if they can help people with sporadic inclusion body myositis, a muscle disease that causes progressive weakness. If the drugs work, they may slow down the disease and help you stay stronger longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 45 and 75 years old
- You have been diagnosed with sporadic inclusion body myositis (a rare muscle disease that causes weakness)
- You can walk at least 20 feet (6 meters) with or without a walking aid, but not supported by another person
- You have not taken a complement inhibitor (a type of immune medication) before
- You are willing to get meningococcal and pneumococcal vaccines, or have had them recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called nerandomilast in people with active inflammatory muscle disease (myositis) that is not well controlled with current treatments. It aims to see if the drug can improve muscle strength and overall disease activity.
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
This trial tests an experimental medicine (BMS-986553) for people with autoimmune diseases that have not improved with other treatments. It aims to see if the drug is safe and helpful for conditions like lupus, myositis, scleroderma, rheumatoid arthritis, and Sjögren's disease.
This study follows people with inflammatory myositis over time to learn more about the condition. If you join, you may receive closer monitoring and contribute to research that could improve future treatments.
This trial is testing a new drug (a JAK inhibitor) for people with rare inflammatory diseases like Behçet's, myositis, or IgG4-related disease that hasn't improved with standard treatments. The goal is to see if it can help control symptoms and reduce inflammation.
Hear when a new Idiopathic Inflammatory Myopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.